AzTrials
AzTrials

Inguinal Hernia RepairNCT02537860

Paravertebral Block for Inguinal Hernia Repair in Elderly

A study testing Paravertebral block injections from T12 to L2, Paravertebral block injections between T11 and L3 and Herniorrhaphy in people with Inguinal Hernia Repair, run by Makassed General Hospital at 1 site in Lebanon.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This prospective double-blinded clinical trial is intended to compare three nerve stimulator- guided paravertebral block injections versus five injections for elderly patients undergoing hernia repair regarding intraoperative hemodynamic stability and postoperative pain. Read more about this study

Who is it for?
Ages 65 years and older
Conditions the study is for
Inguinal Hernia Repair
What is being tested?
Paravertebral block injections from T12 to L2, Paravertebral block injections between T11 and L3 and Herniorrhaphy
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
200 participants
Where
1 siteLebanon
Study dates
Dec 2015to 30 Dec 2017
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 65 years and older
  • All sexes
  • No healthy volunteers
  • Older adult

Who may be able to join

  • patients admitted to undergo elective unilateral inguinal hernia repair
  • patients with ASA II, III or IV

Who cannot join

  • bilateral inguinal hernia
  • incarcerated hernia
  • emergency cases
  • known history of allergic reactions to local anesthesia
  • bleeding disorders
  • neurological disorders
  • infection at site of injection

Trial locations and contacts

1 site in 1 country.

Lebanon1 site
  • Makassed General Hospital

    Beirut

Other trials in Lebanon

About this study

Official title: Paravertebral Block for Inguinal Hernia Repair in Elderly: Randomized Double-blinded Clinical Trial

This prospective double-blinded clinical trial is intended to compare three nerve stimulator- guided paravertebral block injections versus five injections for elderly patients undergoing hernia repair regarding intraoperative hemodynamic stability and postoperative pain.

Read the detailed description

Introduction

The most effective anesthetic technique for inguinal hernia repair remains a controversial issue; however, paravertebral block (PVB) has resulted in significant postoperative analgesia, less postoperative nausea and vomiting (PONV) and short hospital stay compared to general anesthesia (GA), spinal anesthesia (SA) and ilioinguinal nerve block.

Elderly patients usually have higher risk for developing mental disturbances and cardiopulmonary complications following GA. Hence, elderly patients may benefit from PVB. Although PVB has shown satisfactory outcome; nevertheless, there is no standardized PVB regarding the technique and number of injections.

Based on this background, the objective of this prospective double-blinded study is to compare three nerve stimulator- guided PVB injections versus five injections for elderly patients undergoing hernia repair regarding intraoperative hemodynamic stability and postoperative pain.

Methods Following approval of the Institutional Review Board, written informed consent will be obtained from 200 patients aged above 65 years with ASA II, III or IV admitted to undergo elective unilateral inguinal hernia repair between September 2015 and September 2016.

The sealed envelope technique is used to divide the patients into two groups. Group III (100 patients) will receive three PVB injections from T12 to L2 and placebo at T11 and L3. Group V (100 patients) will receive five PVB injections between T11 and L3. The anesthetist, surgeon, patient and data collector are all blind to the patients' group.

ECG leads, pulse oximetry and non-invasive oscillometric arterial pressure are attached. Patients will be given 1 µg/kg intravenous (IV) fentanyl (Fentanyl Hameln 10 ml, 0.05 mg/ml, Hameln Pharmaceuticals, Germany) as premedication. Unilateral PVB will be performed while the patient is in the lateral decubitus position with the side to be operated being upwards. Sites of injection are marked 2.5-3 cm lateral to the midline of the vertebral column.

Paravertebral block technique Following aseptic preparation of the skin, the injection sites are infiltrated with 0.1 ml of lidocaine 1% each using an 8 mm, 30 G needle (BD Micro-Fine Plus, Becton Dickinson and company, USA). PVB injections are done using a 100 mm 22 G nerve stimulator needle (Stimuplex, B.Braun, Melsungen, Germany). The injections begin at L3 and proceed upwards reaching to T11. The needle is introduced perpendicularly to the skin at the site of the injection point using the following nerve stimulator settings: 5mA, 9V and 2Hz. The stimulating needle is gently manipulated into a position to allow for an adequate muscular response with a stimulating current of 0.4-0.8 mA. Then, the injection is performed. Block onset is determined by cold test and pinprick test.

In order to preserve the double blindness of this clinical trial, two syringes will be used for both groups. The first syringe labeled (A) (20 ml) is filled with 15 mL of solution and used to perform equal injections at the levels T12, L1, and L2 (5mL each). The second syringe labeled (B) (10 ml) is used to inject the solution at the levels T11 and L3 (5 ml each).

To ensure equal anesthetic dose of 75 mg of bupivacaine for each patient, the syringes are prepared as follows:

For group V, both syringes (A) and (B) contain 3mg of bupivacaine/ml whereas for group III, the syringe (A) is prepared with 5 mg bupivacaine/ml while syringe (B) contains placebo.

To allow for adequate blinding, the solution used for injection (saline or local anesthetic mixture) is prepared by an independent nurse outside the operating room.

If a patient feels pain during the surgery, 50 - 100 µg IV fentanyl will be given and followed by 0.4-0.5 mg/kg propofol if needed while keeping the patient responsive to verbal stimulation. If the latter is not sufficient, the patient is converted to GA.

Data Collection Demographic and preoperative variables are collected. Time to perform the block, intraoperative hemodynamic monitoring (MAP and HR) are noted during the entire surgery and recorded pre-incision, at skin incision, at inguinal hernia sac traction, and upon wound closure. Supplemental intraoperative fentanyl and propofol is recorded. Surgery duration, incidence of PONV and numbness are noted.

Patients' satisfaction is also assessed based on their comfort and activity during the procedure, intra- and postoperatively. Patient's comfort is determined by: feeling of pain, PONV, and negative memory of the procedural experience. The patient's activity is based on the ability to sit, move and walk. Patients rate these on a scale of one to three ranging from satisfied, partially satisfied, and unsatisfied. Surgeon's satisfaction is based on the overall intra- and postoperative status of the patient. It is measured based on the following: patient's movement or feeling pain during the operation, self-transportation from the surgical table to stretcher, and postoperative pain.

Postoperative pain is assessed during the first five postoperative days (0 hr, 6 hr, 12 hr, and day 1 till day 5) using the Verbal Numeric Rating Scale (VNRS) (0 no pain and 10 worst possible pain). Patients will be discharged the same day once they had urinated and demonstrated ability to tolerate oral diet. Data will be collected during the hospital stay by residents blind to the patient's group. Patients will be contacted by the same resident during the follow-up period through daily phone calls.

Being tested
Paravertebral block injections from T12 to L2, Placebo at T11 and L3, Paravertebral block injections between T11 and L3, Herniorrhaphy, Intravenous (IV) fentanyl

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Paravertebral block injections from T12 to L2Other

    Three anesthetic injections are done

  • Placebo at T11 and L3Other

    Two injections that contain saline are performed

  • Paravertebral block injections between T11 and L3Other

    Five anesthetic injections are done

  • HerniorrhaphyProcedure or surgery

    Unilateral inguinal hernia repair

  • Intravenous (IV) fentanylDrug

    Patients will be given 1 μg/kg intravenous (IV) fentanyl as premedication

  • BupivacaineDrug

    Each patient will receive 75 mg bupivacaine during PVB

Study groups in NCT02537860
Study groupRoleWhat they receive
Three PVB injectionsExperimentalPatients will receive three PVB injections from T12 to L2 and placebo at T11 and L3
Receives: Other: Paravertebral block injections from T12 to L2; Other: Placebo at T11 and L3; Procedure: Herniorrhaphy; Drug: Intravenous (IV) fentanyl; Drug: Bupivacaine
Five PVB injectionsExperimentalPatients will receive five PVB injections between T11 and L3.
Receives: Other: Paravertebral block injections between T11 and L3; Procedure: Herniorrhaphy; Drug: Intravenous (IV) fentanyl; Drug: Bupivacaine

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Mean arterial pressure (MAP) for hemodynamic stability

    Measured: Patients will be monitored during the operation, an expected average of 90 minutes

Secondary outcomes (1)
  1. Pain assessed through the Verbal Numeric Rating Scale (VNRS).

    Measured: 5 postoperative days

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted2 Sep 2015 (estimated)
  2. Study startDec 2015
  3. Primary completion30 Dec 2017
  4. Study completion30 Dec 2017

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
200 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02537860
Sponsor's protocol ID
08252015
Status last verified
Jan 2018
First submitted
25 Aug 2015
Last updated
3 Jan 2018
Results posted
No
Data monitoring committee
No

Publications

  • Naja Z, Kanawati S, Khatib ZE, Ziade F, Nasreddine R, Naja AS. Three versus five lumbar paravertebral injections for inguinal hernia repair in the elderly: a randomized double-blind clinical trial. J Anesth. 2019 Feb;33(1):50-57. doi: 10.1007/s00540-018-2582-9. Epub 2018 Nov 16.

    PubMed 30446826

Questions about this trial

What is this clinical trial studying?

A study testing Paravertebral block injections from T12 to L2, Paravertebral block injections between T11 and L3 and Herniorrhaphy in people with Inguinal Hernia Repair, run by Makassed General Hospital at 1 site in Lebanon.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 3 Jan 2018. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Lebanon. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Mean arterial pressure (MAP) for hemodynamic stability (time frame: Patients will be monitored during the operation, an expected average of 90 minutes). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02537860, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Jan 2018.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in